The effect of rivaroxaban low doses on the stable angina of the II–III functional class clinical manifestations and the quality of life in patients with ischemic heart disease

Aim      To evaluate the effect of low-dose rivaroxaban on quality of life of patients and clinical manifestations of functional class (FC) II-III stable angina.

Material and methods  26 patients with ischemic heart disease (IHD) with FC II-III stable angina, who were newly prescribed rivaroxaban 2.5 mg twice a day in combination with acetylsalicylic acid 75-100 mg, were followed for 10 weeks. During the first (before the beginning of treatment) and the last weeks of study, patients kept diaries, in which they reported angina attacks and short-acting nitrate intake, filled in an angina questionnaire (SAQ), and underwent electrocardiogram (ECG) Holter monitoring (HM).

Results The treatment was associated with decreases in the frequency of angina attacks (by 19.5 %; р=0.027) and the number of taken short-acting nitrate pills (by 17.1 %; р=0.021) and an improvement of quality of life according to stability scales (р=0.042). Data from ECG HM showed decreases in the number and duration of ischemic episodes (p≤0.05).

Conclusion      The treatment of IHD patients with rivaroxaban 2.5 mg twice a day in combination with acetylsalicylic acid 75-100 mg for 2 mos. was associated with decreased frequency of angina attacks, reduced requirement for short-acting nitrate, and with improvement of quality of life.

1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425

2. Barbarash O.L., Karpov Yu.A., Kashtalap V.V., Boshchenko A.A., Ruda M.Ya., Akchurin R.S. et al. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):201–50. DOI: 10.15829/1560-4071-2020-4076

3. Karpov Yu.A., Kukharchuk V.V., Lyakishev A.A., Lupanov V.P., Panchenko E.P., Komarov A.L. et al. Diagnosis and treatment of chronic ischemic heart disease. Cardiology bulletin. 2015;10(3):3–33.

4. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2018;391(10117):205–18. DOI: 10.1016/S0140-6736(17)32458-3

5. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017;377(14):1319–30. DOI: 10.1056/NEJMoa1709118

6. Xie C, Hang Y, Zhu J, Li C, Jiang B, Zhang Y et al. Benefit and risk ofadding rivaroxaban in patients with coronary artery disease: A systematic review and meta‐analysis. Clinical Cardiology. 2021;44(1):20–6. DOI: 10.1002/clc.23514

7. Borst O, Münzer P, Alnaggar N, Geue S, Tegtmeyer R, Rath D et al. Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction. Blood Advances. 2018;2(6):715–30. DOI: 10.1182/bloodadvances.2017013573

8. Karel M, Mastenbroek T, Nagy M, Coenen D, Chaouyâ W, Brouns A et al. PB005: Effects of Aspirin and Rivaroxaban Treatment on Murine Arterial Vessel Wall Remodelling and Thrombus Activity. Research and Practice in Thrombosis and Haemostasis. 2018;2(Suppl 1):PB005. [Av. at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032109/]. DOI: 10.1002/rth2.12125

9. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, Mc-Donnell M et al. Development and evaluation of the Seattle Angina questionnaire: A new functional status measure for coronary artery disease. Journal of the American College of Cardiology. 1995;25(2):333–41. DOI: 10.1016/0735-1097(94)00397-9

10. Shore S, Smolderen KG, Kennedy KF, Jones PG, Arnold SV, Cohen DJ et al. Health Status Outcomes in Patients With Acute Myocardial Infarction Aſter Rehospitalization. Circulation: Cardiovascular Quality and Outcomes. 2016;9(6):777–84. DOI: 10.1161/CIRCOUTCOMES.116.002883

11. Martsevich S.Yu., Kutishenko N.P., Deev A.D. The assessment of nicorandil effect on the quality of life in patients with stable angina in the “KVAZAR” study. Rational Pharmacotherapy in Cardiology. 2016;12(6):654–60. DOI: 10.20996/1819-6446-2016-12-6-654-660

12. Makarov L.M., Komolyatova V.N., Kupriyanova O.O., Pervova E.V., Ryabykina G.V., Sobolev A.V. et al. National russian guidelines on application of the methods of Holter monitoring in clinical practice. Russian Journal of Cardiology. 2014;19(2):6–71. DOI: 10.15829/1560-4071-2014-2-6-71

13. Hara T, Phuong PT, Fukuda D, Yamaguchi K, Murata C, Nishimoto S et al. Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E–Deficient Mice. Circulation. 2018;138(16):1706–19. DOI: 10.1161/CIRCULATIONAHA.118.033544

14. Antoniak S, Rojas M, Spring D, Bullard TA, Verrier ED, Blaxall BC et al. Protease-Activated Receptor 2 Deficiency Reduces Cardiac Ischemia/Reperfusion Injury. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30(11):2136–42. DOI: 10.1161/ATVBAHA.110.213280

15. Liu J, Nishida M, Inui H, Chang J, Zhu Y, Kanno K et al. Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction. Journal of Atherosclerosis and Thrombosis. 2019;26(10):915–30. DOI: 10.5551/jat.48405

16. Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015;242(2):639–46. DOI: 10.1016/j.atherosclerosis.2015.03.023

17. Guo X, Kolpakov MA, Hooshdaran B, Schappell W, Wang T, Eguchi S et al. Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload. JACC: Basic to Translational Science. 2020;5(1):69–83. DOI: 10.1016/j.jacbts.2019.10.006

18. Mastenbroek TG, Karel MFA, Nagy M, Chayoua W, Korsten EIJ, Coenen DM et al. Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery. Scientific Reports. 2020;10(1):19360. DOI: 10.1038/s41598-020-76377-8

19. Iba T, Aihara K, Yamada A, Nagayama M, Tabe Y, Ohsaka A. Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. Thrombosis Research. 2014;133(2):276–80. DOI: 10.1016/j.thromres.2013.11.013

20. Vilaseca M, García-Calderó H, Lafoz E, García-Irigoyen O, Avila MA, Reverter JC et al. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology. 2017;65(6):2031–44. DOI: 10.1002/hep.29084

21. Lee J, Nakanishi R, Li D, Shaikh K, Shekar C, Osawa K et al. Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis. American Heart Journal. 2018;206:127–30. DOI: 10.1016/j.ahj.2018.08.007